Document is current
Any future updates will be listed below
-
Authors
Sebata, Akemi https://orcid.org/0009-0009-8616-8835
Nagao, Takako https://orcid.org/0000-0002-1154-7090
Matsukawa, Tomoko
Maeno, Yuko https://orcid.org/0009-0006-8195-0594
Suzuki, Miwako
Yoshikawa, Yoichiro https://orcid.org/0009-0009-5027-250X
Ibe, Shiro
Fukuda, Akiko https://orcid.org/0000-0001-5855-2084
Wang, Dong
-
Funding
Funding for this research was provided by:
ViiV Healthcare K.K.
- License Information
-
More Information
Article History
Received: 6 November 2025
Accepted: 17 February 2026
First Online: 30 March 2026
Declarations
:
: Akemi Sebata, Takako Nagao, Tomoko Matsukawa, Yuko Maeno, Miwako Suzuki, Yoichiro Yoshikawa, Shiro Ibe, Akiko Fukuda and Dong Wang are employed by ViiV Healthcare K.K.
: This post-marketing surveillance has been conducted by CMIC HOLDINGS Co., Ltd. on behalf of ViiV Healthcare K.K. in compliance with the relevant Japanese regulations (Ministerial Ordinance on GPSP; MHLW No. 171 of December 20, 2004, the amended ordinance, and the related notifications). The study protocol was reviewed and approved by the PMDA, the Japanese regulatory authority, and subsequently approved by the ethics committees at each participating study site. Under the GPSP regulations, written informed consent from patients is not required in post-marketing surveillance. However, the protocol specified that aggregated and analyzed results may be disseminated in scientific reports. Prior to treatment initiation, each potential participant received a detailed explanation regarding the use of the single-agent DTG or DTG/ABC/3TC, and verbal consent for therapy was obtained from all individuals before enrollment. All collected data were anonymized.
